Effect of Vitamin D on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome
2019年7月12日 更新者：Hull University Teaching Hospitals NHS Trust
The Effect of Colecalciferol (Vitamin D) on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome (PCOS) - a Double Blind Randomised Placebo-controlled Study
This is a double blind randomised placebo-controlled study involving women with polycystic ovary syndrome (PCOS).
The patients will be randomised either to Vitamin D 3200 IU or placebo for three months.
The main hypothesis of this study is "Vitamin D improves hormonal, metabolic and cardiovascular risk markers in women with PCOS".
研究概览
详细说明
Polycystic ovary syndrome (PCOS) is a very common condition in women which could present with irregular periods, excessive hair growth on body, acne and cysts in the ovaries.
PCOS is also associated with increased risk of problems later in life like diabetes, high cholesterol levels and heart disease.
One of the risk factors for having increased incidence of such problems in PCOS patients could be low vitamin D levels as many women with polycystic ovary syndrome (PCOS) are vitamin D deficient.
Vitamin D supplementation may have a beneficial effect on insulin levels and fat around the abdomen.
It has been seen in previous research studies that low level of vitamin D is related to a greater risk of diabetes and heart disease.
Low vitamin D levels are also associated with fat in the liver.
The amount of fat in the liver is a sign of early liver disease.
So, in this study the investigators want to supplement women having PCOS and vitamin D deficiency with vitamin D (3,200 IU) and examine the effects on hormones related to PCOS and risk factors for diabetes and heart disease in them.
研究类型
介入性
注册 (实际的)
40
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习地点
-
-
East Yorkshire
-
Hull、East Yorkshire、英国、HU3 2RW
- Michael White Centre for Diabetes and Endocrinology
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 45年 (成人)
接受健康志愿者
不
有资格学习的性别
女性
描述
Inclusion Criteria:
- Caucasian women, aged 18-45 years, with confirmed diagnosis of PCOS based on all three diagnostic criteria of the Rotterdam consensus [21].
- Irregular periods with raised FAI
- Vitamin D < 50 nmol/L.
Exclusion Criteria:
- Non-classical 21-hydroxylase deficiency, hyperprolactinaemia, Cushing's disease and androgen-secreting tumours will be excluded by appropriate tests if clinically indicated.
- Any concurrent illness including type 2 diabetes, subjects who are on any medication (including medications that interfere with calceotrophic hormones) for the preceding 6 months.
- Women planning to conceive.
- Women who are using any oral or implantable contraceptives or any other treatments likely to affect ovarian function, insulin sensitivity or lipids for at least 3 months before entering the study. Stable dose of metformin for 3 months is allowed. Subjects will be advised to use barrier contraception during the study period.
- eGFR<60.
- Hypersensitivity to vitamin D or any of the excipients in the product.
- Peanut or soya allergy.
- Nephrolithiasis.
- Diseases or conditions resulting in hypercalcaemia and/or hypercalciuria.
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：卫生服务研究
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器：Vitamin D3, 3200IU
Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
|
Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
|
|
安慰剂比较：Placebo
Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
|
Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
|
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Cardiovascular risk assessment by hs-CRP, HOMA (fasting glucose & insulin) and fasting lipid profile
大体时间：Three months supplementation with Vitamin D3 3200IU or placebo
|
Three months supplementation with Vitamin D3 3200IU or placebo
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Hormonal parameters including testosterone, SHBG and FAI.
大体时间：Three months supplementation with Vitamin D3 3200IU or placebo
|
Three months supplementation with Vitamin D3 3200IU or placebo
|
|
Inflammatory marker hs-CRP
大体时间：Three months supplementation with Vitamin D3 3200IU or placebo
|
Three months supplementation with Vitamin D3 3200IU or placebo
|
|
Endothelial function by EndoPAT
大体时间：Three months supplementation with Vitamin D3 3200IU or placebo
|
Three months supplementation with Vitamin D3 3200IU or placebo
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员：Thozhukat Sathyapalan, MD, FRCP、University of Hull
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
有用的网址
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2015年7月1日
初级完成 (实际的)
2016年11月1日
研究完成 (实际的)
2016年11月1日
研究注册日期
首次提交
2015年7月23日
首先提交符合 QC 标准的
2015年7月29日
首次发布 (估计)
2015年7月31日
研究记录更新
最后更新发布 (实际的)
2019年7月16日
上次提交的符合 QC 标准的更新
2019年7月12日
最后验证
2019年7月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.